The Central Taiwan Science Park Administration invited three park companies, Surglasses, Microware Precision, and Maxima Biotech, to host the 'Precision Health Program Results Presentation' today. The event showcased the achievements in the development of precision health medical devices, focusing on upgrading the medical device industry in central Taiwan and enhancing the quality of healthcare for the people.
As of the end of November this year, there are a total of 56 companies in the biotechnology industry at the Central Taiwan Science Park, including Pharmally International (6446), Chang Sheng Biotechnology, Forever Optical, Zhenghan Biotechnology, Rich Marine, U-life Biotech, Full-Microware Precision, Union Genomics, Taiwan Lead Biotech, TCI Healthtech, and Surglasses, with a total investment of 17.075 billion NT dollars.
As of the end of August this year, the biotechnology industry's revenue was 7.155 billion NT dollars, a growth of 9.7% compared to the same period last year. Among them, the revenue of medical device manufacturers was 3.307 billion NT dollars, an increase of 11.2% compared to the same period last year.
Xu Maoxin, Director of the Central Taiwan Science Park Administration, stated that to implement the government's six major core strategic industries policy, the 'Central Taiwan Precision Health Industry Cross-Boundary Promotion Plan' has been implemented since the fiscal year 111. With 'Precision Health' as the core, it assists park companies in collaborating with surrounding medical centers and research institutions, engaging in cross-domain cooperation for product development and clinical verification, boosting research and development, and capturing domestic and international market opportunities in precision medical industry.
The results presented at this event include the "AR Augmented Reality Computer Surgery Navigation System" developed by Surglasses. It is the first AR spine surgery navigation system in Taiwan to obtain TFDA Class II medical device license. It features a patented technology that only requires one C-arm for positioning navigation, helping to improve surgical accuracy and reduce operating time. The system has been deployed in numerous domestic hospitals and internationally.
In addition, the company completed a Pre-A round of financing with a total amount of $6.5 million USD in November this year, demonstrating strong market confidence in the company's products.
Microware Precision has achieved success in the development of orthopedic and dental implants and surgical instrument manufacturing. The collaboration with Yang Ming University resulted in the development of the "Tandry Femoral Head PRF Repair Kit and Trauma Implant/Instrument Kit," providing a complete clinical solution. The instrument removes necrotic femoral head and obtains patient PRF (platelet-rich fibrin), mixes with autologous bone or artificial bone to form trabecular bone, and is implanted into the bone cavity, increasing the success rate of orthopedic surgery.
Maxima Biotech, in collaboration with National Cheng Kung University, focuses on the research and development of minimally invasive instruments, specifically the 'Wireless Ultrasonic Knife.' Leveraging the R&D capabilities in central Taiwan, the company aims to create locally developed and mass-produced high-end minimally invasive surgical instruments, increasing the safety of minimally invasive surgery and shortening patient recovery time.
Xu Maoxin mentioned that the Central Taiwan Science Park Administration aims to 'link production, academia, research, and medical cooperation in central Taiwan to facilitate clinical verification of precision health products.' The goal is to deepen local research and development and manufacturing, promote domestically produced products, and collaborate with medical institutions in central Taiwan to facilitate the commercialization and market expansion of domestic biotechnology products.
Related News
#udnnews #Yam #The Central News Agency
